MPiangDuo Tablet 12.5/850 mg
Empagliflozin 12.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Myeongmun Pharmaceutical Co., Ltd.
MFDS item code 202302725 · Approved 2023.09.12
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used to help control blood sugar in adult patients with type 2 diabetes who require combination therapy with empagliflozin and metformin. It serves as an adjunct to diet and exercise to effectively manage blood sugar levels. It is particularly suitable for patients with cardiovascular disease, and safety-related precautions can be confirmed through professional guidelines according to clinical trial results. For these reasons, this medication plays an important role in diabetes treatment by helping control blood sugar and reduce cardiovascular risks.
The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other medicines, such as insulin, the recommended dose of this medicine is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient’s existing metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from concomitant therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their existing doses of empagliflozin and metformin. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see sections 4. Adverse Reactions and 6. Interactions under Precautions for Use). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If a dose of this medicine is missed, take it as soon as you remember. However, do not take a double dose at one time; in this case, skip the missed dose. Special populations Patients with renal impairment No dose adjustment is necessary for patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated using the individual single-ingredient products of empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see section 3. Use with caution in the following patients, item 1, under Precautions for Use). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately (see section 2. Do not administer to the following patients, item 2, under Precautions for Use). Elderly patients In patients 75 years of age and older, renal function and the risk of volume depletion should be considered.
This medication is used for diabetes treatment and helps control blood sugar. While taking this medication, caution is needed due to the risk of rare side effects, such as severe lactic acidosis. Lactic acidosis can result in excessive buildup of lactic acid in the body, leading to a dangerous condition, which could be life-threatening if severe. Additionally, when taken with insulin or other diabetes medications, there is a risk of hypoglycemia, which means blood sugar levels may become too low. This medication should not be administered to patients with moderate to severe renal impairment, patients with severely compromised liver function, patients in acute infection or dehydration states, or women who are pregnant or breastfeeding. Prior to exams using iodine contrast agents, this medication should be temporarily discontinued, and should only be resumed after confirming normal kidney function post-examination. In cases of surgery, this medication should also be stopped 48 hours before the procedure and only resumed after confirming normal kidney function recovery post-surgery. Careful observation for symptoms of dehydration or hypotension is required in patients at risk of fluid loss or in the elderly. Increased urination, urinary tract infection, or genital infection symptoms may occur during treatment, and if such symptoms persist, consultation with a physician is advised. This medication may lower vitamin B12 levels, so regular blood tests for monitoring are recommended. Alcohol consumption may increase the risk of lactic acidosis, so excessive drinking should be avoided during treatment. If any unusual symptoms or discomfort occur during the course of treatment, immediate notification to medical personnel is necessary, especially if symptoms of lactic acidosis or ketoacidosis arise (fatigue, muscle pain, shortness of breath, abdominal pain, etc.), as prompt medical attention is required. Finally, this medication is not recommended for children and adolescents under 18 years of age, as safety and efficacy have not been established in this age group.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture. It is important to maintain the storage temperature between 1 and 30 degrees Celsius.
Pink-tinted white, oval biconvex film-coated tablet
60 tablets/box [(10 tablets/PTP x 6)], 10 tablets/box [(10 tablets/PTP x 1)], 60 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin 12.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Myeongmun Pharmaceutical Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.